Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Detection of Immunoglobulin IgA and IgG Against Human Papilloma Virus

Full text
Goncalves, Ana Katherine [1] ; Lima Machado, Paula Renata [2] ; de Souza, Luanda Canario [2] ; Ferreira Costa, Ana Paula [2] ; Gimenes, Fabricia [3] ; Consolaro, Marcia Lopes [3] ; Crispim, Janaina Oliveira [2] ; Eleuterio, Jr., Jose [4] ; Giraldo, Paulo Cesar [5]
Total Authors: 9
[1] Univ Fed Rio Grande do Norte, Dept Obstet & Gynecol, BR-59012570 Natal, RN - Brazil
[2] Univ Fed Rio Grande do Norte, Dept Toxicol & Clin Anal, BR-59012570 Natal, RN - Brazil
[3] Univ Estadual Maringa, Dept Clin Anal & Biomed, Sect Clin Cytol, Maringa, Parana - Brazil
[4] Univ Fed Ceara, Dept Obstet & Gynecol, Fortaleza, Ceara - Brazil
[5] Univ Estadual Campinas, Dept Obstet & Gynecol, Campinas, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: VIRAL IMMUNOLOGY; v. 27, n. 9, p. 471-477, NOV 1 2014.
Web of Science Citations: 2

The interest in human papilloma virus (HPV) seropositivity has increased considerably since HPV vaccines have become available worldwide. The aim of this study was to assess the performance of enzyme-linked immunosorbent assay (ELISA) in analyzing serum samples provided from women with and without genital DNA-HPV infection confirmed by polymerase chain reaction (PCR), for detection of specific antibodies of the isotypes IgG and IgA recognizing HPV-16 and -18, as well as virus-like particles (VLPs). From August to December 2013, 50 sexually active female patients between 18 and 35 years of age from the outpatient clinic at the university hospital were enrolled. In order to test them, positive controls were obtained from patients with HPV-induced lesions and who were DNA-HPV positive confirmed by PCR. A specific assay was used to identify antibodies to HPV VLPs by ELISA. The samples were divided into HPV positive and negative, and an ELISA detecting IgA and IgG anti-HPV-VLP was carried out. The effectiveness of ELISA and the kappa (k) index was obtained from the values entered in the receiver operating characteristic (ROC) curves for IgG and IgA. IgG-VLP-HPV-16 showed a good correlation between ELISA and PCR (k=0.75), and IgG-VLP-HPV-18 showed a very good correlation between ELISA and PCR (k=0.84). While the IgA antibody correlation was also positive, although weaker, IgA-VLP-HPV-16 was moderate (k=0.45) and IgA-VLP-HPV-18 good (k=0.66). The efficacy of the assay concerning IgG was: sensitivity, specificity, and accuracy were 82.3%, 92%, and 88% to IgG-VLP-HPV-16, and 100%, 92%, and 94% to IgG-VLP-HPV-18. The assay concerning IgA was: sensitivity, specificity, and accuracy were 64.7%, 80%, and 73.8% to IgA-VLP-HPV-16, and 100%, 80%, and 84.8% to IgA-VLP-HPV-18. IgG and IgA antibodies against HPV-16 and -18 can be detected in unvaccinated individuals by using the VLP that serve as the basis for bivalent HPV vaccine. The values for ELISA assays and the values found for IgG correlate good/very good with HPV-16/18 detected by PCR. (AU)

FAPESP's process: 11/19960-9 - Cervico-vaginal humoral response (IgA secretora) in women wich received the quadrivalent vaccine against HPV
Grantee:Paulo César Giraldo
Support Opportunities: Regular Research Grants